Medacist Implements COVID-19 Specific Therapeutic Analytics

News

Medacist recognizes that the current focus of the healthcare community has shifted towards combating the national healthcare crisis – COVID-19. In an effort to assist our customers with information pertinent to these shifting practices, we have rolled out COVID-19 specific therapeutic analytics and analysis across our solutions. With this implementation of COVID-19 therapeutic analytics, Medacist will provide our customers with a tailored perspective to the Coronavirus practice within their organization.
 
It is Medacist’s goal is to deliver innovative healthcare analytics solutions that deliver a positive impact on patient safety. As such, our first priority is our customers and the patients they serve. We believe adding this logic will greatly assist our customers with efforts to combat COVID-19 by proactively monitoring therapies being administered to treat patients affected with the Coronavirus, across the entire organization, by facility or clinical practice area. 

Below are the COVID-19 therapeutic analytics’ medications monitored. These medications are split out into two categories – primary and secondary.
 
Primary Category

  • Chloroquine
  • Hydroxychloroquine
  • Zithromax (Azithromycin or ZPAK)

Secondary Category

  • Lopinavir
  • Ritonavir
  • Remdesivir

Please reach out to us with any questions at info@medacist.com.

Stay safe and healthy.

COVID-19 Therapeutic Analytics